Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03721341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

Study acronym: SABR-COMET 10
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site details revised at 1 of 14 sites
    • Publications: details revised at 2 of 2 entries
  2. Re-verified, no change to tracked fieldsv18
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 14 of 14 sites
    v17
  4. Enrollment target: 159 to 204v16
  5. Study sites: 13 to 14v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 12 to 13v14
  2. Site contacts updated at 1 of 12 sitesv13
  3. Study sites: 9 to 12v12
  4. Study sites: 8 to 9v11
  5. Study sites: 7 to 8v10
  6. Study sites: 6 to 7v9
  7. Study sites: 5 to 6v8
  8. Study sites: 4 to 5v7
  9. Site details revised at 1 of 4 sitesv6
  10. Study sites: 3 to 4v5
  11. Study sites: 2 to 3v4
  12. Study sites: 1 to 2v3
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 2019 to Feb 22, 2019
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
David Palma
6 trials monitored
See 1 trial at risk
In patients with a limited oligometastatic burden (cancer has spread but is not yet considered metastatic), emerging evidence suggests that treatment of all sites of disease with ablative therapies can improve patient outcomes, including overall- and progression-free survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10 metastatic deposits appears promising, yet it is unclear if all patients with greater than 3 oligometastatic lesions benefit from ablative therapies in terms of improved Overall Survival (OS), Progression Free Survival (PFS), or quality of life. The purpose of this study is to assess the impact of SABR, compared to standard of care treatment, on overall survival, oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10 metastatic lesions.
Trial Details
NCT Number NCT03721341
Lead Sponsor David Palma
Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), British Columbia Cancer - Centre for the North, Beaston West of Scotland Cancer Centre, London Health Sciences Centre
Conditions
(from sponsor)		 Metastatic Tumors
Related terms Neoplasm Metastasis
Enrollment 204 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov